Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics

Katie Kompoliti, Charles Howard Adler, R. Raman, J. H. Pincus, M. T. Leibowitz, J. J. Ferry, L. Blasucci, John Nathaniel Caviness, S. Leurgans, W. M. Chase, L. C. Yones, E. Tan, P. Carvey, C. G. Goetz

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

The authors studied the pharmacokinetics of levodopa (LD) with and without pramipexole (PPX) in men and postmenopausal women with PD. Patients on stable dose of carbidopa/LD were randomized to receive escalating doses of placebo or PPX over 7 weeks. LD and PPX pharmacokinetics were performed after a single test dose 25/100 of carbidopa/LD, before initiation of PPX or placebo, at 1.5 mg/d and 4.5 mg/d of PPX or placebo. Compared to men, women had greater LD bioavailability. PPX did not alter LD bioavailability, and PPX pharmacokinetics were equivalent in men and women.

Original languageEnglish (US)
Pages (from-to)1418-1422
Number of pages5
JournalNeurology
Volume58
Issue number9
StatePublished - May 14 2002
Externally publishedYes

Fingerprint

Levodopa
Pharmacokinetics
Placebos
Biological Availability
pramipexole

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Kompoliti, K., Adler, C. H., Raman, R., Pincus, J. H., Leibowitz, M. T., Ferry, J. J., ... Goetz, C. G. (2002). Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology, 58(9), 1418-1422.

Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. / Kompoliti, Katie; Adler, Charles Howard; Raman, R.; Pincus, J. H.; Leibowitz, M. T.; Ferry, J. J.; Blasucci, L.; Caviness, John Nathaniel; Leurgans, S.; Chase, W. M.; Yones, L. C.; Tan, E.; Carvey, P.; Goetz, C. G.

In: Neurology, Vol. 58, No. 9, 14.05.2002, p. 1418-1422.

Research output: Contribution to journalArticle

Kompoliti, K, Adler, CH, Raman, R, Pincus, JH, Leibowitz, MT, Ferry, JJ, Blasucci, L, Caviness, JN, Leurgans, S, Chase, WM, Yones, LC, Tan, E, Carvey, P & Goetz, CG 2002, 'Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics', Neurology, vol. 58, no. 9, pp. 1418-1422.
Kompoliti K, Adler CH, Raman R, Pincus JH, Leibowitz MT, Ferry JJ et al. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology. 2002 May 14;58(9):1418-1422.
Kompoliti, Katie ; Adler, Charles Howard ; Raman, R. ; Pincus, J. H. ; Leibowitz, M. T. ; Ferry, J. J. ; Blasucci, L. ; Caviness, John Nathaniel ; Leurgans, S. ; Chase, W. M. ; Yones, L. C. ; Tan, E. ; Carvey, P. ; Goetz, C. G. / Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. In: Neurology. 2002 ; Vol. 58, No. 9. pp. 1418-1422.
@article{3bd98f7a244b40328e11d08c354da672,
title = "Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics",
abstract = "The authors studied the pharmacokinetics of levodopa (LD) with and without pramipexole (PPX) in men and postmenopausal women with PD. Patients on stable dose of carbidopa/LD were randomized to receive escalating doses of placebo or PPX over 7 weeks. LD and PPX pharmacokinetics were performed after a single test dose 25/100 of carbidopa/LD, before initiation of PPX or placebo, at 1.5 mg/d and 4.5 mg/d of PPX or placebo. Compared to men, women had greater LD bioavailability. PPX did not alter LD bioavailability, and PPX pharmacokinetics were equivalent in men and women.",
author = "Katie Kompoliti and Adler, {Charles Howard} and R. Raman and Pincus, {J. H.} and Leibowitz, {M. T.} and Ferry, {J. J.} and L. Blasucci and Caviness, {John Nathaniel} and S. Leurgans and Chase, {W. M.} and Yones, {L. C.} and E. Tan and P. Carvey and Goetz, {C. G.}",
year = "2002",
month = "5",
day = "14",
language = "English (US)",
volume = "58",
pages = "1418--1422",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics

AU - Kompoliti, Katie

AU - Adler, Charles Howard

AU - Raman, R.

AU - Pincus, J. H.

AU - Leibowitz, M. T.

AU - Ferry, J. J.

AU - Blasucci, L.

AU - Caviness, John Nathaniel

AU - Leurgans, S.

AU - Chase, W. M.

AU - Yones, L. C.

AU - Tan, E.

AU - Carvey, P.

AU - Goetz, C. G.

PY - 2002/5/14

Y1 - 2002/5/14

N2 - The authors studied the pharmacokinetics of levodopa (LD) with and without pramipexole (PPX) in men and postmenopausal women with PD. Patients on stable dose of carbidopa/LD were randomized to receive escalating doses of placebo or PPX over 7 weeks. LD and PPX pharmacokinetics were performed after a single test dose 25/100 of carbidopa/LD, before initiation of PPX or placebo, at 1.5 mg/d and 4.5 mg/d of PPX or placebo. Compared to men, women had greater LD bioavailability. PPX did not alter LD bioavailability, and PPX pharmacokinetics were equivalent in men and women.

AB - The authors studied the pharmacokinetics of levodopa (LD) with and without pramipexole (PPX) in men and postmenopausal women with PD. Patients on stable dose of carbidopa/LD were randomized to receive escalating doses of placebo or PPX over 7 weeks. LD and PPX pharmacokinetics were performed after a single test dose 25/100 of carbidopa/LD, before initiation of PPX or placebo, at 1.5 mg/d and 4.5 mg/d of PPX or placebo. Compared to men, women had greater LD bioavailability. PPX did not alter LD bioavailability, and PPX pharmacokinetics were equivalent in men and women.

UR - http://www.scopus.com/inward/record.url?scp=0037076466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037076466&partnerID=8YFLogxK

M3 - Article

C2 - 12011296

AN - SCOPUS:0037076466

VL - 58

SP - 1418

EP - 1422

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 9

ER -